(Q37870920)

24 August 2017

1 reference

title

Motesanib and advanced NSCLC: experiences and expectations (English)

1 reference

24 August 2017

author

George R Blumenschein

series ordinal

2

object named as

George R Blumenschein

1 reference

24 August 2017

author name string

Kanwal Pratap Singh Raghav

series ordinal

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

2 May 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

20

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

859-869

1 reference

Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Isolation of a tumor factor responsible for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Vascular permeability factor (VPF, VEGF) in tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Motesanib diphosphate in progressive differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.579103

10.1517/13543784.2011.579103

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference